Analysts Set Expectations for Recordati Industria Chimica e Farmaceutica S.p.A.’s FY2022 Earnings (OTCMKTS:RCDTF)

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF – Get Rating) – Investment analysts at Jefferies Financial Group issued their FY2022 earnings per share (EPS) estimates for Recordati Industria Chimica e Farmaceutica in a research report issued to clients and investors on Wednesday, May 18th. Jefferies Financial Group analyst J. Vane-Tempest anticipates that the company will post earnings per share of $2.19 for the year. Jefferies Financial Group also issued estimates for Recordati Industria Chimica e Farmaceutica’s FY2023 earnings at $2.44 EPS, FY2024 earnings at $2.68 EPS, FY2025 earnings at $2.93 EPS and FY2026 earnings at $3.35 EPS.

Separately, Deutsche Bank Aktiengesellschaft dropped their target price on shares of Recordati Industria Chimica e Farmaceutica from €47.00 ($48.96) to €44.00 ($45.83) and set a “hold” rating for the company in a research report on Monday, February 28th. One analyst has rated the stock with a sell rating and four have issued a hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $54.00.

Shares of Recordati Industria Chimica e Farmaceutica stock opened at $42.03 on Friday. Recordati Industria Chimica e Farmaceutica has a 1 year low of $42.03 and a 1 year high of $42.03. The firm has a market cap of $8.67 billion, a PE ratio of 18.68 and a beta of 0.21. The company has a 50 day simple moving average of $42.03 and a two-hundred day simple moving average of $55.74.

Recordati Industria Chimica e Farmaceutica Company Profile (Get Rating)

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat.

Further Reading